GlobeNewswire: MediWound Ltd. Contains the last 10 of 264 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T18:56:16ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/21/2850096/0/en/MediWound-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Provides-Company-Update.html?f=22&fvtc=4&fvtv=21216MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update2024-03-21T11:00:00Z<![CDATA[$19 million revenue in 2023; $24 million projected revenue in 2024NexoBrid® commercially launched in U.S., Japan, IndiaPotential blockbuster EscharEx® to begin Phase III in the second half of 2024$42 million cash runway through profitability]]>https://www.globenewswire.com/news-release/2024/03/14/2846241/0/en/MediWound-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=21216MediWound to Report Fourth Quarter and Full Year 2023 Financial Results2024-03-14T12:00:00Z<![CDATA[Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time]]>https://www.globenewswire.com/news-release/2024/02/12/2827407/0/en/MediWound-Announces-Positive-Results-in-Head-to-Head-Comparison-of-EscharEx-vs-SANTYL-within-the-ChronEx-Phase-II-Randomized-Controlled-Study.html?f=22&fvtc=4&fvtv=21216MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study2024-02-12T12:00:00Z<![CDATA[Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU) Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous leg ulcers (VLU)]]>https://www.globenewswire.com/news-release/2024/02/05/2823453/0/en/MediWound-to-Participate-in-Two-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=21216MediWound to Participate in Two Upcoming Investor Conferences2024-02-05T13:00:00Z<![CDATA[YAVNE, Israel, Feb. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Oppenheimer 34th Annual Life Sciences Conference, taking place virtually on February 13-14, 2024, as well as the upcoming TD Cowen 44th Annual Health Care Conference, taking place in Boston on March 4-6, 2024.]]>https://www.globenewswire.com/news-release/2024/01/09/2806137/0/en/MediWound-Announces-that-FDA-has-Accepted-for-Review-the-Supplement-to-the-NexoBrid-BLA-to-Include-Pediatric-Patients-with-Severe-Thermal-Burns.html?f=22&fvtc=4&fvtv=21216MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns2024-01-09T12:00:00Z<![CDATA[If approved, NexoBrid will serve as an effective non-surgical treatment for both pediatric and adult burn patients in the U.S.]]>https://www.globenewswire.com/news-release/2023/12/28/2801651/0/en/MediWound-Secures-Additional-U-S-Department-of-Defense-Funding-to-Advance-NexoBrid-Development-for-the-U-S-Army.html?f=22&fvtc=4&fvtv=21216MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army2023-12-28T12:00:21Z<![CDATA[Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million]]>https://www.globenewswire.com/news-release/2023/12/21/2799949/0/en/MediWound-Announces-Peer-Reviewed-Publication-of-EscharEx-Mechanism-of-Action-Study-Assessing-Its-Effects-on-Biofilm-and-Microbial-Loads.html?f=22&fvtc=4&fvtv=21216MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads2023-12-21T13:00:00Z<![CDATA[Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement]]>https://www.globenewswire.com/news-release/2023/11/21/2783933/0/en/MediWound-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Company-Update.html?f=22&fvtc=4&fvtv=21216MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update2023-11-21T12:02:00Z<![CDATA[NexoBrid® commercially launched in U.S. and Japan; Company prioritizes operational resources to meet increased global demand]]>https://www.globenewswire.com/news-release/2023/11/21/2783924/0/en/MediWound-Announces-Appointment-of-Shmulik-Hess-Ph-D-as-Chief-Operating-Officer-and-Chief-Commercial-Officer.html?f=22&fvtc=4&fvtv=21216MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer2023-11-21T12:00:00Z<![CDATA[YAVNE, Israel, Nov. 21, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced the appointment of Shmulik Hess, Ph.D. to the positions of Chief Operating Officer and Chief Commercial Officer effective as of December 1, 2023. Dr. Hess will lead and oversee all operational and commercial activities at MediWound.]]>https://www.globenewswire.com/news-release/2023/11/14/2780053/0/en/MediWound-to-Report-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=21216MediWound to Report Third Quarter 2023 Financial Results2023-11-14T13:02:26Z<![CDATA[Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time]]>